Why Drugs Fail in Clinical Trials

Most drugs fail due to underlying biological risk rather than execution. Understanding these risks is critical for biotech investors, pharma business development teams, and analysts evaluating drug assets.

Traditional analysis often focuses on trial design, endpoints, or regulatory strategy. However, failure is frequently driven by deeper biological mismatches between the drug mechanism and the disease context.

MBRS Bio Terminal analyzes biological signals to evaluate:

• Clinical failure risk
• Asset–indication mismatch
• Biotech investment mispricing

By focusing on biology as the primary determinant of outcome, MBRS enables earlier identification of high-risk assets and uncovers differentiation across competing therapies.